This three-wave syndicated research series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for relapsed/refractory multiple myeloma. This series is based on primary research data collected at one month, three months, and one year postcommercial availability of Darzalex and Empliciti. Along with awareness and sources of familiarity, our analysis assesses U.S. hematological oncologists’ trial, adoption, and use of these agents, including anticipated future trends. Our content provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Johnson & Johnson/Janssen’s and Bristol-Myers Squibb’s promotional efforts, and benchmarking against other agents for multiple myeloma.

Table of contents

  • Multiple Myeloma - Emerging Therapies - Darzalex/Empliciti Launch Tracking Wave 2 (US)

Author(s): Izabela Ammermann, PhD; Dana Gheorghe

Izabela Ammermann, Ph.D., M.Sc., is a business insights analyst in the oncology division at Decision Resources Group. She is a specialist in multiple myeloma and pancreatic cancer and has expertise in chronic lymphocytic leukemia. Dr. Ammermann holds a Ph.D. in molecular biology from the Technical University of Munich and a M.Sc. in biotechnology from the Polish Academy of Sciences. Prior to joining Decision Resources Group, Dr. Ammermann worked as a postdoctoral research associate (Marie Curie research fellow) at Imperial College London. Dr. Ammermann has published several peer-reviewed papers.

Dana Gheorghe, Ph.D., is a senior business insights analyst on the Oncology team at Decision Resources Group, specializing in non-Hodgkin’s lymphoma and renal cell carcinoma, with expertise in multiple myeloma and metastatic colorectal cancer. Her previous experience includes postdoctoral positions at Imperial College London and the Marie Curie Research Institute. Dr. Gheorghe holds a Ph.D. in cellular biology and biochemistry from the University of Sheffield and a B.Sc./Honors in Molecular Biology from the University of Edinburgh.


Related Reports

Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast

Market Outlook The availability of premium-priced branded agents prescribed in doublet, triplet, and quadruplet regimens, particularly Darzalex-based therapies, has had an...

View Details

Multiple Myeloma - Geographic Focus: China - Multiple Myeloma | China In-Depth | China

MARKET OUTLOOKMultiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the introducti...

View Details

Multiple Myeloma | Disease Landscape and Forecast | G7 | 2019

Market Outlook The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed in not just doublet an...

View Details

Multiple Myeloma - Access & Reimbursement - Detailed, Expanded Analysis (US)

MARKET OUTLOOKSuccessive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapies. W...

View Details